Skip to Content

Generic Prezcobix Availability

Prezcobix is a brand name of cobicistat/darunavir, approved by the FDA in the following formulation(s):

PREZCOBIX (cobicistat; darunavir ethanolate - tablet;oral)

  • Manufacturer: JANSSEN PRODS
    Approval date: January 29, 2015
    Strength(s): 150MG;EQ 800MG BASE [RLD]

Has a generic version of Prezcobix been approved?

No. There is currently no therapeutically equivalent version of Prezcobix available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prezcobix. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • .alpha.-and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
    Patent 5,843,946
    Issued: December 1, 1998
    Inventor(s): Vazquez; Michael L. & Mueller; Richard A. & Talley; John J. & Getman; Daniel & DeCrescenzo; Gary A. & Freskos; John N.
    Assignee(s): G.D. Searle & Co.
    .alpha.- and .beta.-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Patent expiration dates:
    • December 1, 2015
      ✓ 
      Patent use: TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
      ✓ 
      Drug product
    • June 1, 2016
      ✓ 
      Pediatric exclusivity
  • Fitness assay and associated methods
    Patent 7,470,506
    Issued: December 30, 2008
    Inventor(s): Erickson; John W. & Gulnik; Sergei V. & Mitsuya; Hiroaki & Ghosh; Arun K.
    Assignee(s): The United States of America as represented by the Department of Health and Human Services Board of Trustees of the University of Illinois
    The present invention provides an assay for determining the biochemical fitness of a biochemical species in a mutant replicating biological entity relative to its predecessor. The present invention further provides a continuous fluorogenic assay for measuring the anti-HIV protease activity of protease inhibitor. The present invention also provides a method of administering a therapeutic compound that reduces the chances of the emergence of drug resistance in therapy. The present invention also provides a compound of formula (I) or a pharmaceutically acceptable salt, a prodrug, a composition, or an ester thereof, wherein A is a group of formulas (A), (B), (C) or (D); R1, R2, R3, R5 or R6 is H, or an optionally substituted and/or heteroatom-bearing alkyl, alkenyl, alkynyl, or cyclic group; Y and/or Z are CH2, O, S, SO, SO2, amino, amides, carbamates, ureas, or thiocarbonyl derivatives thereof, optionally substituted with an alkyl, alkenyl, or alkynyl group; n is from 1 to 5; X is a bond, an optionally substituted methylene or ethylene, an amino, O or S; Q is C(O), C(S), or SO2; m is from 0 to 6; R4 is OH, ═O (keto), NH2, or alkylamino, including esters, amides, and salts thereof; and W is C(O), C(S), S(O), or SO2. Optionally, R5 and R6, together with the N—W bond of formula (I), comprises a macrocyclic ring.
    Patent expiration dates:
    • June 23, 2019
      ✓ 
      Patent use: TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
    • December 23, 2019
      ✓ 
      Pediatric exclusivity
  • Pseudopolymorphic forms of a HIV protease inhibitor
    Patent 7,700,645
    Issued: April 20, 2010
    Inventor(s): Vermeersch; Hans Wim Pieter & Thoné; Daniel Joseph Christiaan & Janssens; Luc Donné Marie-Louise
    Assignee(s): Tibotec Pharmaceuticals Ltd.
    New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.
    Patent expiration dates:
    • December 26, 2026
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • June 26, 2027
      ✓ 
      Pediatric exclusivity
  • Modulators of pharmacokinetic properties of therapeutics
    Patent 8,148,374
    Issued: April 3, 2012
    Inventor(s): Desai; Manoj C. & Liu; Hongtao & Xu; Lianhong
    Assignee(s): Gilead Sciences, Inc.
    The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
    Patent expiration dates:
    • September 3, 2029
      ✓ 
      Patent use: TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pseudopolymorphic forms of a HIV protease inhibitor
    Patent 8,518,987
    Issued: August 27, 2013
    Assignee(s): Janssen R&D Ireland
    New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.
    Patent expiration dates:
    • February 16, 2024
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • August 16, 2024
      ✓ 
      Pediatric exclusivity
  • Method of treating HIV infection
    Patent 8,597,876
    Issued: December 3, 2013
    Assignee(s): The United States of America, as represented by the Secretary, Department of Health and Human Services Board of Trustees of the University of Illinois
    Disclosed is a method of treating human immunodeficiency virus (HIV) infection in an antiretroviral treatment-experienced mammal, which involves administering to the mammal an effective amount of a compound of the formula: or a pharmaceutically acceptable salt, a prodrug, or an ester thereof, or a pharmaceutically acceptable composition of the compound, the salt, the prodrug, or the ester thereof, wherein A, X, Q, W, m, and R2-R6 are as defined herein.
    Patent expiration dates:
    • June 23, 2019
      ✓ 
      Patent use: TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
    • December 23, 2019
      ✓ 
      Pediatric exclusivity
  • α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
    Patent RE42889
    Issued: November 1, 2011
    Inventor(s): Vazquez; Michael L. & Mueller; Richard A. & Talley; John J. & Getman; Daniel P. & DeCrescenzo; Gary A. & Freskos; John N. & Heintz; Robert M. & Bertenshaw; Deborah E.
    Assignee(s): G.D. Searle LLC
    α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Patent expiration dates:
    • October 19, 2016
      ✓ 
      Drug product
    • April 19, 2017
      ✓ 
      Pediatric exclusivity
  • α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
    Patent RE43596
    Issued: August 21, 2012
    Inventor(s): Vazquez; Michael L. & Mueller; Richard A. & Talley; John J. & Getman; Daniel P. & DeCrescenzo; Gary A. & Freskos; John N. & Heintz; Robert M. & Bertenshaw; Deborah E.
    Assignee(s): G.D. Searle LLC
    α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Patent expiration dates:
    • May 9, 2017
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • November 9, 2017
      ✓ 
      Pediatric exclusivity
  • α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
    Patent RE43802
    Issued: November 13, 2012
    Inventor(s): Vazquez; Michael L. & Mueller; Richard A. & Talley; John J. & Getman; Daniel P. & DeCrescenzo; Gary A. & Freskos; John N. & Bertenshaw; Deborah E. & Heintz; Robert M.
    Assignee(s): G.D. Searle LLC
    α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Patent expiration dates:
    • October 19, 2016
      ✓ 
      Patent use: TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
    • April 19, 2017
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide